Abstract
The abilities of the orally active platinum anti-tumor drug JM216 [trans-bis-acetato-cis-dichloroammine (cyclohexylamine) platinum (IV)] to induce the biosynthesis of metallothionein (MT) were investigated in rabbits given oral administrations or injections s. c. It is revealed that oral administration of JM216 can induce the MT synthesis in the liver but not in the kidney. The hepatic MT contained 7.11 ± 0.11 Zn and only little Pt or Cu. Injections of JM216 to rabbits can greatly elevate the MT levels in the liver, but increase the renal MT levels only slightly. The MT content as well as Pt concentration in the liver was much higher than that in the kidney. The metal stoichiometry in the purified renal MT was determined to be 4.41 ± 0.04 Zn, 0.36 ± 0.11 Pt and 2.50 ± 0.18 Cu per mole protein. The hepatic MT was still characterized as Zn7MT. Both the treatment with oral administration and injections s.c. cannot lead to the increase of Pt content in the kidney. The oxidation state of platinum in the MT from the kidney was determined to be +2 by X-ray photoelectron spectroscopy. As compared with zinc compounds, JM216 was a very poor stimulator for MT biosynthesis in vivo. Pre-injections with Zn(NO3)2 significantly enhanced the MT levels as well as the Pt concentration compared with that resulting from injections with JM216 alone. Based on the experimental data, the role of MT in relation to its involvement in the metabolism and the mechanism of detoxification of Pt(IV) complexes are discussed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Baker AD, Befferidge D. 1972 In: Photoelectron Spectroscopy Chemical and Analytical Aspects.
Blatter EE, Vollono JF, Krishman BS et al. 1984 Interaction of the antitumor agents cis,cis,trans-Pt(IV)(NH 3 ) 2 Cl 2 (OH)2 and cis,cis,trans-Pt(IV)[(CH 3 ) 2 CHNH 2 ]Cl 2 (OH)2 and their reduction products with PM 2 DNA. Biochemistry 23, 4817–4823.
Bongers J, Bell JU, Richardson DE. 1988 Platinum(II) binding to metallothionein. J Inorg Biochem 34, 55–62.
Cherian MG, Goyer RA. 1978 Metallothioneins and their role in the metabolism and toxicity of metals. Life Sci 23, 1–10.
Comeau RD, McDonald KW. 1992 Gram scale purification and preparation of rabbit liver metallothionein. Prep Biochem 22, 151–156.
Giandomenico CM, Abrams MJ, Kelland LR et al. 1991 In: Howell SB. ed. Platinum and Other Metal Coordination Complexes in Cancer Chemotherapy, 93–100.
Giandomenico CM, Abrams MJ, Murrer BA et al. 1995 Carboxylation of kinetically inert platinum (IV) hydroxy complexes. An entree into orally active platinum (IV) antitumor agents. Inorg Chem 34, 1015–1021.
Good M, Vasak M. 1986 Spectroscopy properties of the cobalt(II) substituted-fragment of rabbit liver metallothionein. Biochemistry 25, 3328–3334.
Katrib A. 1980 The reduction of Pt(IV) to Pt(II) by X-Ray and argon ion bombardment; evidence from X-Ray photoelectron spectrosopty. J Electron Spectros Relat Phenom 18, 275–281.
Kelland LR, Abel G, McKeage MJ et al. 1993 Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine (IV): an orally active platinum drug. Cancer Res 53, 2581–2586.
Loehrer PJ, Einhorn LH. 1984 Cisplatin. Ann Intern Med 100, 704– 713.
McKeage MJ, Mistry P, Ward J et al. 1995 Phase I and pharmacological study of an oral platinum complex (JM216): dose dependent pharmacokinatic with single dose administration. Cancer Chemother. Pharmacol 36, 451–457.
McKeage MJ, Raynaud F, Ward J et al. 1997 Phase I and pharma-cokinatic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol 15, 2691–2700.
Naganuma A, Satoh M, Imura N. 1987 Prevention of lethal and renal toxicity of cis-diamminedichloroplatinum (II) by induction of metallothionein synthesis without compromising its antitumor activity in mice. Cancer Res 47, 983–987.
Neijt JP, Ten Bokkel Huinink WW, Van Der Burg MEL et al. 1991 Long-term survival in ovarian cancer. Eur J Cancer 27, 1367–1372.
Nielson KB, Atkin CL, Winge DR. 1985 Distinct metal-binding configurations in metallothionein. J BiolChem 260, 5342–5350.
Ozols ARF. 1991 Ovarian cancer: new clinical approaches. Cancer Treat Rev Suppl A, 18, 77–83.
Raynaud FI, Boxell FE, Goddard P et al. 1996 Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products. Anticancer Res 16, 1857–1862.
Raynaud FI, Mistry P, Donaghue A et al. 1996 Biotransformation of the platinum drug JM216 following oral administration to cancer patients.Cancer Chemother Pharmacol 38, 155–162.
Sharma RP, Edwards LR. 1983 cis-platinum: subcellular distribution and binding to cytosolic ligands. Biochem Pharmacol 32, 2665–2669.
Suzuki CAM, Ohta H, Albores A et al. 1990 Induction of metalloth-ionein synthesis by zinc in cadmium pretreated rats. Toxicology 63(3), 273–284.
Talman EG, Bruning W, Reedijk JL et al. 1997 Crystal and molecular structures of asymmetric cis-and trans-platinum (II/IV) compounds and their reactions with DNA fragments. Inorg Chem 36, 854–861.
Wong BE, Giandomenico CM. 1999 Current status of platinum-based antitumor drugs. Chem Rev 99, 2451–2466.
Zhong WQ, Zhang Q, Tang WX et al. 1997 Interaction of iproplatin and Na 2 PtCl 6 with Metallothionein in vivo. J Inorg Biochem 66,159–164.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Xing, B., Zhu, H., Wang, Y. et al. Binding properties of an orally active platinum anti-tumor drug JM216 with metallothionein in vivo. Biometals 13, 203–208 (2000). https://doi.org/10.1023/A:1009236927190
Issue Date:
DOI: https://doi.org/10.1023/A:1009236927190